2-[18F]-fluoro-2-desoxy-D-glucose positron emission tomography initial staging impacts on survival in Hodgkin lymphoma

Table 3 The three- and five-year overall survival and event free survival of conventional staging and metabolic staging in initial staging of hodgkin lymphoma patients

Survival	150Patients CS	117Patients MS	267Total patients
Three-year EFS
Stage I	91.7%	100.0%	93.7%
Stage II	78.7%	84.4%	80.9%
Early stage	80.7%	85.6%	82.6%
Stage III	79.7%	76.7%	78.4%
Stage IV	63.7%	65.2%	64.5%
Advanced stage	71.0%	70.0%	70.5%
Five-year EFS
Stage I	91.7%	100.0%	93.7%
Stage II	77.0%	84.4%	79.8%
Early stage	79.3%	85.6%	81.5%
Stage III	76.5%	69.0%	73.1%
Stage IV	58.6%	44.8%	53.7%
Advanced stage	66.7%	53.6%	61.9%
Three-year OS
Stage I	91.7%	100.0%	93.7%
Stage II	93.2%	97.2%	94.8%
Early stage	93.0%	97.5%	94.6%
Stage III	94.2%	96.3%	95.2%
Stage IV	77.2%	74.2%	75.7%
Advanced stage	84.9%	82.8%	83.9%
Five-year OS
Stage I	91.7%	100.0%	93.7%
Stage II	91.2%	97.2%	93.3%
Early stage	91.3%	97.5%	93.4%
Stage III	94.2%	90.9%	92.9%
Stage IV	71.1%	74.2%	72.5%
Advanced stage	81.5%	80.7%	81.1%

OS: Overall survival; EFS: Event free survival; CS: Conventional stage; MS: Metabolic staging.